Intravitreal injection is the most frequently performed eye procedure in the world and is an essential component in the management of sight-threating retinal diseases and conditions. Given the seriousness and range of diseases treated and the risks of the procedure, retina specialists must weigh the pros and cons of each individual treatment. Complexities guiding injection treatment are multifaceted and involve patient-history review, careful examination, diagnostic testing selection and interpretation, customized medical decision-making, and follow-up considerations.
Methods:
This article by the Intravitreal Injection Task Force Committee of the American Society of Retina Specialists documents the intricacies and necessary components of the intravitreal injection procedure.
Results:
By expert consensus, the task force further recommends ancillary services and decision-making that may accompany intravitreal injection visits, when appropriate, to monitor response to treatment, adjust treatment, and manage additional considerations in the same or fellow eye.
Conclusions:
Retina specialists can optimize safety and therapeutic outcomes with individualized consideration and customization of intravitreal injection treatment for each patient.
GrzybowskiAToldRSacuS, et al;Euretina Board. 2018 update on intravitreal injections: Euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181–193. doi:10.1159/000486145
2.
VoLVLapakkoZJLederHA, et al.Certification and credentials of intravitreal injection proceduralists in the US. Ophthalmol Retina. 2020;5(5):487–489. doi:10.1016/j.oret.2020.10.006
3.
EmersonGGThompsonJTVoLVMasonRWHLeeGDLederHA; Health Economics Committee, American Society of Retina Specialists. Office examinations–directed treatment paradigms reduce travel burden, decrease treatment cost, and improve quality-adjusted life-years for patients with exudative age-related macular degeneration undergoing antivascular endothelial growth factor therapy. J Vitreoretin Dis. 2020;4(6):472–478. doi:10.1177/2474126420935819
4.
BavingerJCYuYVanderBeekBL. Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab. Retina. 2019;39(10):2004–2011. doi:10.1097/IAE.0000000000002351
5.
KissSDugelPUKhananiAM, et al.Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clin Ophthalmol. 2018;12:1625–1635. doi:10.2147/OPTH.S169143
6.
FiletaJBScottIUFlynnHWJr. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014;45(2):143–149. doi:10.3928/23258160-20140306-08
7.
AveryRLCastellarinAADhootDS, et al.Large silicone droplets after intravitreal bevacizumab (Avastin). Retin Cases Brief Rep. 2019;13(2):130–134. doi:10.1097/ICB.0000000000000570
8.
KhuranaRNChangLKPorcoTC. Incidence of presumed silicone oil droplets in the vitreous cavity after intravitreal bevacizumab injection with insulin syringes. JAMA Ophthalmol. 2017;135(7):800–803. doi:10.1001/jamaophthalmol.2017.1815
9.
HahnPChungMMFlynnHWJr, et al.Postmarketing analysis of aflibercept-related sterile intraocular inflammation. JAMA Ophthalmol. 2015;133(4):421–426. doi:10.1001/jamaophthalmol.2014.5650
10.
WitkinAJHahnPMurrayTG, et al.Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4(4):269–279. doi:10.1177/2474126420930863
11.
StoreyPPPancholyMWibbelsmanTD, et al.Rhegmatogenous retinal detachment after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmology. 2019;126(10):1424–1431. doi:10.1016/j.ophtha.2019.04.037
12.
EhlkenCZiemssenFEterN, et al.Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol. 2020;258(10):2077–2090. doi:10.1007/s00417-020-04798-2
13.
HanJRinellaNTChaoDL. Anesthesia for intravitreal injection: a systematic review. Clin Ophthalmol. 2020;14:543–550. doi:10.2147/OPTH.S223530
14.
PrennerJL. Anesthesia for intravitreal injection. Retina. 2011;31(3):433–434. doi:10.1097/IAE.0b013e31820a686a
15.
TustinAKimSJChomskyAHubbardGB IIIShengJ. Antibacterial properties of 2% lidocaine and reduced rate of endophthalmitis after intravitreal injection. Retina. 2014;34(5):935–942. doi:10.1097/IAE.0000000000000014
16.
StemMSRaoPLeeIJ, et al.Predictors of endophthalmitis after intravitreal injection: a multivariable analysis based on injection protocol and povidone iodine strength. Ophthalmol Retina. 2019;3(1):3–7. doi:10.1016/j.oret.2018.09.013
17.
EntezariMKarimiSAhmadiehHMahmoudiAHParhizgarHYaseriM. A large outbreak of fulminant bacterial endophthalmitis after intravitreal injection of counterfeit bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1851–1856. doi:10.1007/s00417-016-3426-7
18.
BeckKDRahmanEZEllsAMireskandariKBerrocalAMHarperCA III. SAFER-ROP: updated protocol for anti-VEGF injections for retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2020;51(7):402–406. doi:10.3928/23258160-20200702-05
19.
KhanPKhanLMondalP. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2016;64(9):694–696. doi:10.4103/0301-4738.99855
20.
GoldbergRAFlynnHWJrIsomRFMillerDGonzalezS. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):204–208.e1. doi:10.1016/j.ajo.2011.11.035
21.
VanderBeekBLBonaffiniSGMaL. Association of compounded bevacizumab with postinjection endophthalmitis. JAMA Ophthalmol. 2015;133(10):1159–1164. doi:10.1001/jamaophthalmol.2015.2556
22.
VanderBeekBL. The argument for sterile loading of all intravitreal injections and the benefit of replicated results. JAMA Ophthalmol. 2019;137(4):343–344. doi:10.1001/jamaophthalmol.2018.7089
23.
MeloGBEmersonGGDiasCSJr, et al.Release of silicone oil and the off-label use of syringes in ophthalmology. Br J Ophthalmol. 2020;104(2):291–296. doi:10.1136/bjophthalmol-2019-313823
24.
MeloGBFigueiraACMBatistaFAH, et al.Inflammatory reaction after aflibercept intravitreal injections associated with silicone oil droplets released from syringes: a case-control study. Ophthalmic Surg Lasers Imaging Retina. 2019;50(5):288–294. doi:10.3928/23258160-20190503-05
25.
GrzybowskiAKanclerzPMyersWG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol. 2018;29(1):19–32. doi:10.1097/ICU.0000000000000437
26.
OakleyCLVoteBJ. Aqueous chlorhexidine (0.1%) is an effective alternative to povidone-iodine for intravitreal injection prophylaxis. Acta Ophthalmol. 2016;94(8):e808–e809. doi:10.1111/aos.12981
27.
BhavsarARIpMSGlassmanAR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol. 2007;144(3):454–456. doi:10.1016/j.ajo.2007.04.011
28.
ShresthaRKarkiPJoshiSN. Outcome of intravitreal bevacizumab injection without pre and postoperative antibiotics. BMC Ophthalmol. 2020;20(1):145. doi:10.1186/s12886-020-01420-1
29.
SuJZhengLJLiuXQ. Iatrogenic crystalline lens injury during intravitreal injection of triamcinolone acetonide: a report of two cases. World J Clin Cases. 2019;7(22):3784–3791. doi:10.12998/wjcc.v7.i22.3784
30.
RamosMSXuLTSinguriS, et al.Patient-reported complications after intravitreal injection and their predictive factors. Ophthalmol Retina. 2021;5(7):625-632. doi:10.1016/j.oret.2020.09.024
31.
FriedmanDAMasonJO IIIEmondTMcGwinGJr. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina. 2013;33(5):975–981. doi:10.1097/IAE.0b013e3182877585
32.
RahimyEFinemanMSRegilloCD, et al.Speculum versus bimanual lid retraction during intravitreal injection. Ophthalmology. 2015;122(8):1729–1730. doi:10.1016/j.ophtha.2015.02.001
33.
UyarEUlasFSahinSCelebiS. Major factors affecting intraocular pressure spike after intravitreal ranibizumab injection: vitreous reflux and its amount. Eur J Ophthalmol. 2019;29(4):361–367. doi:10.1177/1120672119836613
34.
SaedonHNosekJPhillipsJNarendranNYangYC. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol. 2017;36(4):343–346. doi:10.1080/15569527.2017.1291665
35.
JagerRDAielloLPPatelSCCunninghamETJr. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676–698. doi:10.1097/00006982-200410000-00002
36.
AveryRLBakriSJBlumenkranzMS, et al.Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34(suppl 12):S1–S18. doi:10.1097/IAE.0000000000000399
37.
FungAERosenfeldPJReichelE. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344–1349. doi:10.1136/bjo.2006.099598
38.
WykoffCCCroftDEBrownDM, et al;TREX-AMD Study Group. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122(12):2514–2522. doi:10.1016/j.ophtha.2015.08.009
39.
WenJCMcCannelCAMochonABGarnerOB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129(12):1551–1554.
40.
ShahCPGargSJVanderJFBrownGCKaiserRSHallerJA. Outcomes and risk factors associated with endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028–2034. doi:10.1016/j.ophtha.2011.02.034
41.
XuKChinEKBennettSR, et al.Endophthalmitis after intravitreal injection of vascular endothelial grown factor inhibitors: management and visual outcomes. Ophthalmology. 2018;125(8):1279–1286. doi:10.1016/j.ophtha.2018.01.022
42.
EtminanMMaberleyDABabiukDWCarletonBC. Risk of myocardial infarction and stroke with single or repeated doses of intravitreal bevacizumab in age-related macular degeneration. Am J Ophthalmol. 2016;166:205. doi:10.1016/j.ajo.2016.03.026
43.
CurtisLHHammillBGSchulmanKACousinsSW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128(10):1273–1279. doi:10.1001/archophthalmol.2010.223
44.
CampbellRJGillSSBronskillSEPatersonJMWhiteheadMBellCM. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ. 2012;345:e4203. doi:10.1136/bmj.e4203
45.
HwangDJKimYWWooSJParkKH. Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab. J Korean Med Sci. 2012;27(12):1580–1585. doi:10.3346/jkms.2012.27.12.1580
46.
DalvinLAStarrMRAbouChehadeJE, et al.Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration. JAMA Ophthalmol. 2019;137(5):483–490. doi:10.1001/jamaophthalmol.2018.6891
47.
CarneiroAMBarthelmesDFalcãoMS, et al.Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica. 2011;225(4):211–221. doi:10.1159/000323943
48.
SharmaSJohnsonDAbouammohMHollandsSBrissetteA. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012;47(3):275–279. doi:10.1016/j.jcjo.2012.03.026
49.
IkramMKMitchellPKleinRSharrettARCouperDJWongTY. Age-related macular degeneration and long-term risk of stroke subtypes. Stroke. 2012;43(6):1681–1683. doi:10.1161/STROKEAHA.112.654632
50.
SchmidMKBachmannLMFäsLKesselsAGJobOMThielMA. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2015;99(2):141–146. doi:10.1136/bjophthalmol-2014-305149
51.
KwonJWJeeDLaTY. The association between myocardial infarction and intravitreal bevacizumab injection. Medicine (Baltimore). 2018;97(13):e0198. doi:10.1097/MD.0000000000010198
52.
McCannelCA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–661. doi:10.1097/IAE.0b013e31820a67e4
53.
EdingtonMConnollyJChongNV. Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. Expert Opin Drug Metab Toxicol. 2017;13(12):1217–1224. doi:10.1080/17425255.2017.1404987
54.
KimJEMantravadiAVHurEYCovertDJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146(6):930–934e.1. doi:10.1016/j.ajo.2008.07.007
55.
AtchisonEAWoodKMMattozCGBarryCNLumFMacCumberMW. The real-world effect of intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure. Ophthalmology. 2018;125(5):676–682. doi:10.1016/j.ophtha.2017.11.027
ChanCKMeyerCHGrossJG, et al.Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina. 2007;27(5):541–551. doi:10.1111/j.1442-9071.2008.01710.x
58.
ArevaloJFMaiaMFlynnHWJr, et al.Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213–216. doi:10.1136/bjo.2007.127142
59.
KeanePALiakopoulosSOngchinSC, et al.Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(7):3115–3120. doi:10.1167/iovs.08-1689
60.
SchaalSKaplanHJTezelTH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?Ophthalmology. 2008;115(12):2199–2205. doi:10.1016/j.ophtha.2008.07.007
61.
ForooghianFCukrasCMeyerleCBChewEYWongWT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;29(6):723–731. doi:10.1097/IAE.0b013e3181a2c1c3
62.
ParikhRAveryRLSarojNThompsonDFreundKB. Incidence of new choroidal neovascularization in fellow eyes of patients with age-related macular degeneration treated with intravitreal aflibercept or ranibizumab. JAMA Ophthalmol. 2019;137(8):914–920. doi:10.1001/jamaophthalmol.2019.1947
63.
HoACKleinmanDMLumFC, et al.Baseline visual acuity at wet AMD diagnosis predicts long-term vision outcomes: an analysis of the IRIS Registry. Ophthalmic Surg Lasers Imaging Retina. 2020;51(11):633–639. doi:10.3928/23258160-20201104-05
64.
RosenfeldPJShapiroHTuomiLWebsterMElledgeJBlodiB; MARINA and ANCHOR Study Groups. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118(3):523–530. doi:10.1016/j.ophtha.2010.07.011
65.
CATT Research Group; MartinDFMaguireMGYingGSGrunwaldJEFineSLJaffeGJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908. doi:10.1056/NEJMoa1102673
66.
Bonini FilhoMAde CarloTEFerraraD, et al.Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol. 2015;133(8):899–906. doi:10.1001/jamaophthalmol.2015.1320
